Actively Recruiting
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
Led by Pfizer · Updated on 2026-03-27
600
Participants Needed
1
Research Sites
245 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua
CONDITIONS
Official Title
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)
- Signed and dated informed consent indicating understanding of the study
You will not qualify if you...
- Contraindication to Lorviqua as per local labeling
- Hypersensitivity to Lorviqua or any excipients
- Concomitant use of strong CYP3A4/5 inducers
- Rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose galactose malabsorption
- Does not agree to Pfizer and partner companies using personal information
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pfizer
Seoul, South Korea
Actively Recruiting
Research Team
P
Pfizer CT.gov Call Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here